Anti-interleukin-6

Anti-IL-6 Receptor antibodies: Treatment of Coronavirus-associated pulmonary pathology

During the COVID-19 pandemic, antagonistic antibodies against the IL-6 receptors were tested in clinical trials to assess their use in treating or preventing severe pneumonia in critically ill COVID-19 patients. Such antibodies include tocilizumab and sarilumab. Antibodies against IL-6 itself, such as siltuximab, were also investigated. Also: Levilimab.

Exercise induced IL-6

New research has found IL-6 to be an anti-inflammatory cytokine with multiple beneficial effects when released by contracting muscle as a myokine. IL-6 had previously been classified as a proinflammatory cytokine. Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage. However, it has become evident that eccentric exercises are not associated with a larger increase in plasma IL-6 than exercise involving concentric “nondamaging” muscle contractions. This finding demonstrates that muscle damage is not required to provoke an increase in plasma IL-6 during exercise. In fact, eccentric exercise may result in a delayed peak and a much slower decrease of plasma IL-6 during recovery. Anti-IL-6 therapies should therefore take into consideration the (beneficial) anti-inflammatory effects of myokines generally, including the now-established multiple benefits of muscle-derived Interleukin 6.

IL6 and asthma

Obesity is a known risk factor in the development of severe asthma, and work has suggested that IL-6 plays a role in regulating disease severity in obesity-related asthma.

Luteolin reduces IL-6 production in some neurons.

References

References

1. (2011). "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling". The Journal of Clinical Investigation.
2. (2005). "Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes". Expert Opinion on Therapeutic Targets.
3. (2006). "Interleukin-6: a new therapeutic target". Arthritis Research & Therapy.
4. Stein and Sutherland. (1998). "IL-6 as a drug discovery target". Drug Discovery Today.
5. (2007). "Interleukin-6 – new target in the battle against Ras-induced cancers".
6. (2003). "Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis". Current Opinion in Rheumatology.
7. (2014). "IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab". Annals of the Rheumatic Diseases.
8. (2013). "Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement". Ann. Rheum. Dis..
9. [https://web.archive.org/web/20140424231837/http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf fda.gov]{{full citation needed. (July 2017{{Dead link). (June 2020)
10. (January 2017). "TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis.". Cytokine.
11. [https://www.medpagetoday.com/Rheumatology/Arthritis/65499 FDA Gives Nod to Sarilumab for Rheumatoid Arthritis. 2017]
12. (2 Dec 2008). "UCB Announces Start Of Phase I Study For Antibody Drug Candidate CDP6038".
13. (July 2017). "Article > UCB's RA drug does not overly impress in Phase II".
14. (2013). "The novel guanylhydrazone CPSI-2364 ameliorates ischemia reperfusion injury after experimental small bowel transplantation". Transplantation.
15. (27 Sep 2010). "ArGEN-X Wins €1.5M IWT Grant to Progress Camelid-Derived Human Antibody Pipeline".
16. "RuiYi (Formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody".
17. (30 July 2010). "Formatech to Donate Services to Formulate and Fill Femta Pharmaceuticals' FM101 Monoclonal Antibody under Its "Fillanthrop".
18. (2020-03-16). "Regeneron, Sanofi Launch Clinical Trial of Kevzara as Coronavirus Treatment".
19. "ChinaXiv.org 中国科学院科技论文预发布平台".
20. (2022). "Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs". Acta Biomedica: Atenei Parmensis.
21. (2020-03-19). "EUSA Pharma initiates study of siltuximab to treat Covid-19 patients".
22. (1997). "Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage". The Journal of Physiology.
23. (2013). "Muscle as a secretory organ". Comprehensive Physiology.
24. (2016). "Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts". The Lancet Respiratory Medicine.
25. (2008). "Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1". Proceedings of the National Academy of Sciences of the United States of America.